Mechanism involved in the Circulation of oxidized LDL and its Ratio; An Early Risk Marker in Diabetic and Non-Diabetic Subjects with Coronary Heart Disease
Article Sidebar
-
Coronary Heart Disease, Oxidized Low-Density Lipoprotein, Low-Density Lipoprotein, Diabetes, non-diabetes
Abstract
Under oxidative stress hardening of arteries is linked to oxidative variations in low density lipoproteins and imaginably more than one mechanism is involved in the atherosclerosis, where LDL is oxidized in all the cells of intimal wall during the progression of CHD. Ox-LDL act as a prognosticator of dysfunction in endothelium along with pro-thrombotic, pro-apoptotic, pro-inflammatory properties in subjects suffering from oxidative stress. Circulating ox-LDL is associated with the development of atherosclerosis but also numerous degenerative and age related disease. The objective of our study is to assess the levels of circulating oxidized LDL and its ratio in Diabetic and Non-Diabetic Subjects with CHD. This cross-sectional study was conducted in Department of General Medicine and Master Health check-up OP of SRM Medical College and Research Centre, Tamil Nadu, India. Totally 273 subjects in that 91 CHD patient without Diabetes, 91 CHD patient with diabetes and 91 healthy control in age group of 30 to 55 years and were age and sex matched. After overnight fasting blood samples were collected for analysis. ox-LDL were measured by ELISA method and Lipid Profile is measured using Auto Analyser AU480. Statistical analysis was done using student ‘t’ test and Pearson correlation analysis for the comparison between two groups. When compared to controls the mean level Low Density Lipoprotein and Plasma Oxidized LDL was significantly elevated in CHD group. Significantly positive correlation was observed between plasma oxidized LDL an LDL. The study concludes that increased circulating ox-LDL and its ratio are early risk marker and useful predictor of mortality in patients with CHD.For the diagnosis and treatment of coronary heart disease an appropriate method that reveal the mechanisms which increase circulating LDL and ox-LDL is needed.
Full text article
References
Aerdoso, W. L. D. C., Hsu, I., Ryabets-Lienhard, A., Miyazaki, B. 2014. Endocrine Society 96th Annual Meeting & EXPO Chicago, IL USA (June 20-24, 2014) selected highlights. Pediatric Endocrinology Reviews , 12(2):239–255.
Ali, K. M., Wonnerth, A., Huber, K., Wojta, J. 2012. Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities. British Journal of Pharmacology, 167(6):1177–1194.
Allen, J., Markovitz, J., Jacobs, D. R., Knox, S. S. 2001. Social Support and Health Behavior in Hostile Black and White Men and Women in CARDIA. Psychosomatic Medicine, 63(4):609–618.
Cole, J. H., Sperling, L. S., et al. 2004. Premature coronary artery disease: Clinical risk factors and prognosis. Current Atherosclerosis Reports, 6(2):121– 125.
Fournier, J. A., Cabezón, S., Cayuela, A., Ballesteros, S. M., Cortacero, J. A., Llera, L. S. D. D. L., et al. 2004. Long-term prognosis of patients having acute myocardial infarction when ≤ 40 years of age. The American Journal of Cardiology, 94(8):989–992.
Hadi, H. A. R., Carr, C. S., Suwaidi, J. 2005. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular Health and Risk Management, 1(3):183–198.
Hazen, S. L., Heinecke, J. W., et al. 1997. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. Journal of Clinical Investigation, 99(9):2075–2081.
Holvoet, P., Mertens, A., Verhamme, P., Bogaerts, K., Beyens, G., Verhaeghe, R., Collen, D., Muls, E., de Werf, F. V. 2001. Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 21(5):844–848.
Honing, M. L., Morrison, P. J., Banga, J. D., Stroes, E. S., Rabelink, T. J. 1998. Nitric oxide availability in diabetes mellitus. Diabetes / Metabolism Reviews, 14(3):241–249.
Horton, J. D., Goldstein, J. L., Brown, M. S. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation, 109(9):1125– 1131.
Huang, H., Mai, W., Liu, D., Hao, Y., Tao, J., Dong, Y. 2008. The oxidation ratio of LDL: A Predictor for Coronary Artery Disease. Disease Markers, 24(6):341–349.
Leopold, J. A., Loscalzo, J., et al. 2009. The oxidative risk for atherothrombotic cardiovascular disease. Free Radical Biology and Medicine, 47(12):1673– 1706.
Levitan, I., Volkov, S., Subbaiah, P. V. 2010. Oxidized LDL: Diversity, Patterns of Recognition, and Pathophysiology. Antioxidants & Redox Signaling, 13(1):39–75.
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W. L., Vickers, C, K. 2019. The role of lipids and lipoproteins in atherosclerosis.
Misra, A., Chowbey, P., Makkar, B. M., Vikram, N. K., Wasir, J. S., Chadha, D., Joshi, S. R., Sadikot, S., Gupta, R., Gulati, S., Munjal, Y. P. 2009. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India, 57:163–170.
Mundi, S., Massaro, M., Scoditti, E., Carluccio, M. A., van Hinsbergh, V. W. M., Iruela-Arispe, M. L., Caterina, R. D. 2018. Endothelial permeability, LDL deposition, and cardiovascular risk factors— a review. Cardiovascular Research, 114(1):35–52.
Ndrepepa, G., Braun, S., von Beckerath, N., Mehilli, J., Gorchakova, O., Vogt, W., Schömig, A., Kastrati, A. 2005. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clinica Chimica Acta, 360(1-2):178–186.
Parthasarathy, S., Wieland, E., Steinberg, D. 1989. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proceedings of the National Academy of Sciences, 86(3):1046–1050.
Pranavchand, R., et al. 2013. Current status of understanding of the genetic etiology of coronary heart disease. Journal of Postgraduate Medicine, 59(1):30–30.
Quiñones-Galvan, A., Sironi, A. M., Baldi, S., Galetta, F., Garbin, U., Fratta-Pasini, A., Cominacini, L., Ferrannini, E. 1999. Evidence That Acute Insulin Administration Enhances LDL Cholesterol Susceptibility to Oxidation in Healthy Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(12):2928–2932.
Schindhelm, R. K., van der Zwan, L. P., Teerlink, T., Scheffer, P. G. 2009. Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification? Clinical Chemistry, 55(8):1462–1470.
Sigurdardottir, V., Fagerberg, B., Hulthe, J. 2002. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year- old men (AIR study). Journal of Internal Medicine, 252(5):440–447.
Singh, D., et al. 2016. Effect of Cigarette Smoking on Serum Lipid Profile in Male Population of Udaipur. Biochemistry & Analytical Biochemistry, 5(3).
Steinberg, D., et al. 2002. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nature Medicine, 8(11):1211– 1217.
Steinberg, D., et al. 2009. The LDL modification hypothesis of atherogenesis: an update. Journal of Lipid Research, 50:376–381.
Strong, J. P., et al. 1999. Prevalence and Extent of Atherosclerosis in Adolescents and Young Adults: Implications for Prevention From the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA, 281(8):727–727.
Sukhovershin, R. A., Yepuri, G., Ghebremariam, Y. T. 2015. Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy. Methodist DeBakey Cardiovascular Journal, 11(3):166–171.
Tessari, P., Cecchet, D., Cosma, A., et al. 2010. Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy. Diabetes, 59(9):2152–2159.
Yoshida, H., Sasaki, K., Namiki, Y., Sato, N., Tada, N. 2005. Edaravone, a novel radical scavenger, inhibits oxidative modification of low density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis, 179(1):97–102.
Yoshimoto, R., Fujita, Y., Kakino, A., Iwamoto, S., Takaya, T., Sawamura, T. 2011. The Discovery of LOX-1, its Ligands and Clinical Significance. Cardiovascular Drugs and Therapy, 25(5):379–391.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.